Next Article in Journal / Special Issue
Aptamer Microarrays—Current Status and Future Prospects
Previous Article in Journal
In Silico Genomic Fingerprints of the Bacillus anthracis Group Obtained by Virtual Hybridization
Previous Article in Special Issue
Particle-Based Microarrays of Oligonucleotides and Oligopeptides
Article Menu

Export Article

From the third issue of 2017, Microarrays has changed its name to High-Throughput.

Open AccessReview
Microarrays 2015, 4(2), 98-114; doi:10.3390/microarrays4020098

Reverse Phase Protein Arrays—Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use

Institut für Pathologie, Technische Universität München, Trogerstrasse 18, 81675 München, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Günter Roth
Received: 15 January 2015 / Revised: 9 March 2015 / Accepted: 18 March 2015 / Published: 24 March 2015
(This article belongs to the Special Issue New and Old Technologies for Generation of Microarrays)
View Full-Text   |   Download PDF [862 KB, uploaded 24 March 2015]   |  

Abstract

Reverse Phase Protein Arrays (RPPA) represent a very promising sensitive and precise high-throughput technology for the quantitative measurement of hundreds of signaling proteins in biological and clinical samples. This array format allows quantification of one protein or phosphoprotein in multiple samples under the same experimental conditions at the same time. Moreover, it is suited for signal transduction profiling of small numbers of cultured cells or cells isolated from human biopsies, including formalin fixed and paraffin embedded (FFPE) tissues. Owing to the much easier sample preparation, as compared to mass spectrometry based technologies, and the extraordinary sensitivity for the detection of low-abundance signaling proteins over a large linear range, RPPA have the potential for characterization of deregulated interconnecting protein pathways and networks in limited amounts of sample material in clinical routine settings. Current aspects of RPPA technology, including dilution curves, spotting, controls, signal detection, antibody validation, and calculation of protein levels are addressed. View Full-Text
Keywords: tissue; cancer; personalized medicine; FFPE; protein; antibody; diagnostics; therapy tissue; cancer; personalized medicine; FFPE; protein; antibody; diagnostics; therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Boellner, S.; Becker, K.-F. Reverse Phase Protein Arrays—Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use. Microarrays 2015, 4, 98-114.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Microarrays EISSN 2076-3905 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top